 - On track to initiate three Phase 12 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis GM1, PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe disease - - Opened first U.S. site for PBGM01s Imagine-1 global clinical program and actively recruiting patients; other site activations in progress - - Opening new CMC research and development site to support analytics, assay development, and product testing in 2Q 2021 - - Strengthened financial position with recent public offering that raised 166M in net proceeds - - Management to host conference call today at 8:30 a.m. ET - 